1.Current status and future perspectives on the methods of prognosis evaluation for intrahepatic cholangiocarcinoma.
Gu Wei JI ; Zheng Gang XU ; Shu Ya CAO ; Ke WANG ; Xue Hao WANG
Chinese Journal of Surgery 2023;61(6):467-473
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignant tumor in the liver after hepatocellular carcinoma. Its incidence and mortality rates have increased worldwide in recent years. Surgical resection is the best treatment modality for ICC;however,the overall prognosis remains poor. Accurate evaluation of post operative prognosis allows personalized treatment and improved long-term outcomes of ICC. The American Joint Commission on Cancer TNM staging manual is the basis for the standardized diagnosis and treatment of ICC;however,the contents of stage T and stage N need to be improved. The nomogram model or scoring system established in the analysis of commonly used clinicopathological parameters can provide individualized prognostic evaluation and improve prediction accuracy;however,more studies are needed to validate the results before clinical use. Meanwhile,imaging features exhibit great potential to establish the post operative prognosis evaluation system for ICC. Molecular-based classification provides an accurate guarantee for prognostic assessment as well as selection of populations that are sensitive to targeted therapy or immunotherapy. Therefore,the establishment of a prognosis evaluation system,based on clinical and pathological characteristics and centered on the combination of multidisciplinary and multi-omics,will be conducive to improving the long-term outcomes of ICC after surgical resection in the context of big medical data.
Humans
;
Bile Ducts, Intrahepatic/pathology*
;
Cholangiocarcinoma/pathology*
;
Prognosis
;
Liver Neoplasms/surgery*
;
Bile Duct Neoplasms/pathology*
3.Primary hepatic angiosarcoma: a clinicopathological analysis of nine cases.
S ZHAO ; Y ZHU ; S Y MA ; Q H FAN ; Q X GONG
Chinese Journal of Pathology 2023;52(11):1132-1137
Objective: To investigate the clinical manifestations, histomorphology, and differential diagnosis of primary hepatic angiosarcoma. Methods: Nine cases of primary hepatic angiosarcoma diagnosed in the Department of Pathology, the First Affiliated Hospital of Nanjing Medical University from January 2014 to December 2021 were collected, including biopsy and surgical specimens. The histomorphology, clinical, and radiologic findings were analyzed. The relevant literature was also reviewed. Results: There were six males and three females, aged 30 to 73 years (mean 57 years). Grossly, the growth pattern of the tumor was classified as either mass formation or non-mass formation (sinusoidal). Microscopically, the mass-forming primary hepatic angiosarcoma were further subdivided into vasoformative or non-vasoformative growth patterns; and those non-vasoformative tumors had either epithelioid, spindled, or undifferentiated sarcomatoid features. Sinusoidal primary hepatic angiosarcoma on the other hand presented with markedly dilated and congested blood vessels of varying sizes, with mild to moderately atypical endothelial cells. Follow-up in all nine cases revealed 8 mortality ranging from 1 to 18 months (mean 5 months) from initial diagnosis. One patient was alive with disease within a period of 48 months. Conclusions: Primary hepatic angiosarcoma is a rare entity with a wide spectrum of histomorphology, and often misdiagnosed. It should be considered when there are dilated and congested sinusoids, with overt nuclear atypia. The overall biological behavior is aggressive, and the prognosis is worse.
Male
;
Female
;
Humans
;
Hemangiosarcoma/diagnosis*
;
Endothelial Cells/pathology*
;
Liver Neoplasms/surgery*
;
Prognosis
;
Biopsy
4.Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition).
Chinese Journal of Surgery 2023;61(12):1035-1045
Recurrence of hepatocellular carcinoma (HCC) after surgery is a major factor affecting the efficacy of the treatment of patients. Neoadjuvant treatment is an effective therapeutic method to reduce postoperative recurrence and prolong patient survival. However,there is no generally accepted neoadjuvant treatment regimen that has been proven to be effective so far. Recently,with the progress in systemic antitumor therapies,represented by targeted molecular agents and immune checkpoint inhibitors,and the improvement in local regional therapies,these treatment approaches have shown promising efficacy and safety in the field of neoadjuvant treatment for HCC. Under the organizational leadership of Committee of Digestive Surgery of Chinese Research Hospital Association and Committee of Liver Cancer of Chinese Anti-Cancer Association,Alliance of Chinese Expert Consensus on Neoadjuvant Therapy for Hepatocellular Carcinoma has discussed and revised several times and finally formulated the Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition). This consensus aimed to review the Chinese characteristics of the diagnosis and treatment of HCC,to provide specific guidance and suggestions for preoperative treatment strategies for HCC,and further promote the management of the clinical pathway for neoadjuvant treatment of HCC.
Humans
;
Antineoplastic Agents/therapeutic use*
;
Carcinoma, Hepatocellular/surgery*
;
China
;
Consensus
;
Liver Neoplasms/pathology*
;
Neoadjuvant Therapy
6.Analysis of the diagnosis and treatment of 24 cases of hepatic perivascular epithelioid cell tumor.
Ben LIU ; Wen Yi ZHOU ; Yu Ting XIAO ; Yu Hao CHENG ; Yi Heng GE ; Sheng Dan NIE ; Pin LYU
Chinese Journal of Hepatology 2022;30(8):889-894
Objective: To investigate hepatic perivascular epithelioid cell tumor (PEComa) diagnosis and treatment plan. Methods: 24 cases diagnosed with PEComa clinical manifestations, serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), imaging findings, surgical methods, postoperative hospital stay, pathological results and prognosis were analyzed retrospectively from September 2015 to September 2020. Results: Majority of patients were females (79.2%), aged 41.5±11.4 years. Tumors were predominantly located in the right liver (50.0%). 76.7% of the cases were mostly clinically asymptomatic. AFP, CEA and CA199 indices were all negative. CT mostly showed low density tumor in the plain scan phase, enhanced in the enhancement phase, and enhanced and weakened in portal venous and equilibrium phase (66.7%). MRI manifestations of most tumors were hypointense on T1WI and hyperintense on T2WI (72.7%). B-ultrasound mostly showed hyperechoic mass in the tumor area with punctate vascular shadow (52.9%). Postoperative hospital stay was 9.0±2.4 days for laparoscopic surgery patients (n=13), 13.4±6.3 days for traditional laparotomy (hereinafter referred to as laparotomy, n=10), and 3 days for 1 patient with microwave ablation. All postoperative pathological results were positive for HMB45 and Melan-A. Follow-up results: 21 cases survived normally, with no tumor recurrence in the recent physical examination; two cases had tumor recurrence and they died two and three years after surgery, and one case was lost to follow-up. Conclusion: Hepatic PEComa more commonly occurs in middle-aged women, with no specific features for tumor markers and clinical manifestations. Some imaging findings are specific, so its features can be combined as a basis for diagnosis. Postoperative pathological examination results can confirm the diagnosis. Therefore, surgery remains the initial treatment plan. Microwave ablation and laparoscopic surgery are recommended as the preferred option because of shorter hospital stays and less trauma than open surgery.
Adult
;
Biomarkers, Tumor/analysis*
;
Carbohydrates
;
Carcinoembryonic Antigen
;
Female
;
Humans
;
Liver/pathology*
;
MART-1 Antigen
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Perivascular Epithelioid Cell Neoplasms/surgery*
;
Retrospective Studies
;
alpha-Fetoproteins
7.Splenectomy suppresses growth and metastasis of hepatocellular carcinoma through decreasing myeloid-derived suppressor cells in vivo.
Xin LONG ; Jian WANG ; Jian-Ping ZHAO ; Hui-Fang LIANG ; Peng ZHU ; Qi CHENG ; Qian CHEN ; Yan-Hui WU ; Zhan-Guo ZHANG ; Bi-Xiang ZHANG ; Xiao-Ping CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(5):667-676
The function of the spleen in tumor development has been investigated for years. The relationship of the spleen with hepatocellular carcinoma (HCC), a huge health burden worldwide, however, remains unknown. The present study aimed to examine the effect of splenectomy on the development of HCC and the possible mechanism. Mouse hepatic carcinoma lines H22 and Hepa1-6 as well as BALB/c and C57 mice were used to establish orthotopic and metastatic mouse models of liver cancer. Mice were divided into four groups, including control group, splenectomy control group (S group), tumor group (T group) and tumor plus splenectomy group (T+S group). Tumor growth, metastases and overall survival were assessed at determined time points. Meanwhile, myeloid-derived suppressor cells (MDSCs) were isolated from the peripheral blood (PB), the spleen and liver tumors, and then measured by flow cytometery. It was found that liver cancer led to splenomegaly, and increased the percentage of MDSCs in the PB and spleen in the mouse models. Splenectomy inhibited the growth and progression of liver cancer and prolonged the overall survival time of orthotopic and metastatic models, which was accompanied by decreased proportion of MDSCs in the PB and tumors of liver cancer-bearing mouse. It was suggested that splenectomy could be considered an adjuvant therapy to treat liver cancer.
Animals
;
Carcinoma, Hepatocellular
;
physiopathology
;
surgery
;
Cell Line, Tumor
;
Flow Cytometry
;
Humans
;
Liver Neoplasms
;
physiopathology
;
surgery
;
Mice
;
Myeloid-Derived Suppressor Cells
;
pathology
;
Neoplasms, Experimental
;
physiopathology
;
surgery
;
Spleen
;
physiopathology
;
surgery
;
Splenectomy
;
methods
8.Impact of operative and peri-operative factors on the long-term prognosis of primary liver cancer patients undergoing hepatectomy.
Li-Ning XU ; Ying-Ying XU ; De-Wei GAO
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(4):523-528
This study examined the impact of the operative and peri-operative factors on the long-term prognosis of patients with primary liver cancer undergoing hepatectomy. A total of 222 patients with primary liver cancer who underwent hepatectomy were followed up from January 1986 to December 2010 at Chinese PLA General Hospital. The post-operative complication rate was 14.0% for all cases, 13.7% for hepatocellular carcinoma (HCC), 10.0% for cholangiocarcinoma. The 1-, 3-, 5- and 10-year overall survival rates in patients with primary liver cancer after resection were 76.6%, 57.6%, 41.4%, and 21.0%. The survival rates were significantly higher in the HCC group than in the cholangiocarcinoma group (P=0.000), in the non-anatomical resection group than in the anatomical resection group (P=0.005), in the female group than in the male group (P=0.002), in patients receiving no blood transfusion than in those who were given intra-operative blood transfusion (P=0.000), in patients whose intra-operative blood loss was less than 400 mL than in those who intra-operatively lost more than 400 mL (P=0.000). No significant difference was found in the survival rate between the HBsAg-positive group and the HBsAg-negative group (P=0.532). Our study showed that anatomical resection, blood loss and blood transfusion were predictors of poor survival after hepatectomy for primary liver cancer patients, and concomitant hepatitis B virus infection bore no relation with the post-resection survival.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Hepatocellular
;
blood
;
pathology
;
surgery
;
virology
;
Cholangiocarcinoma
;
blood
;
pathology
;
surgery
;
virology
;
Disease-Free Survival
;
Female
;
Hepatectomy
;
adverse effects
;
Hepatitis B Surface Antigens
;
blood
;
Hepatitis B virus
;
isolation & purification
;
pathogenicity
;
Humans
;
Liver Neoplasms
;
blood
;
pathology
;
surgery
;
virology
;
Male
;
Middle Aged
;
Postoperative Complications
;
blood
;
pathology
;
Prognosis
9.Laparoscopic versus traditional open splenectomy for hepatocellular carcinoma with hypersplenism.
Han-Hua DONG ; Bin MEI ; Fei-Long LIU ; Zhi-Wei ZHANG ; Bi-Xiang ZHANG ; Zhi-Yong HUANG ; Xiao-Ping CHEN ; Wan-Guang ZHANG
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(4):519-522
This study aimed to examine the efficacy of the laparoscopic vs. traditional open splenectomy for hepatocellular carcinoma (HCC) with hypersplenism. Between 2002 and 2013, 51 Chinese HCC patients with hypersplenism underwent either simultaneous laparoscopic splenectomy plus anticancer therapies (Lap-S&A) (n=25) or traditional open splenectomy plus anti-cancer therapies (TOS&A) (n=26). The outcomes were reviewed during and after the operation. Anti-cancer therapies for HCC included laparoscopic hepatectomy (LH) and laparoscopic microwave ablation (LMA). The results showed that there was no significant difference in the operating time between the two groups, but the blood loss and blood transfusion were less, pain intensity after surgery was weaker, the time to first bowel movement, time to the first flatus and postoperative hospital stay were shorter, and the postoperative complication rate and the readmission rate were lower in the Lap-S&A group than in the TO-S&A group. Two patients in the Lap-S&A group and one patient in the TO-S&A group died 30 days after surgery. However, no significant difference in the mortality rate was noted between the two groups. It was concluded that simultaneous Lap-S&A holds the advantages of more extensive indications, lower complication incidence and less operative expenditure than conventional open approach and it is a feasible and safe approach for HCC with hypersplenism.
Adult
;
Aged
;
Carcinoma, Hepatocellular
;
complications
;
pathology
;
surgery
;
Female
;
Hepatectomy
;
Humans
;
Hypersplenism
;
complications
;
pathology
;
surgery
;
Laparoscopy
;
Liver
;
pathology
;
surgery
;
Liver Neoplasms
;
complications
;
pathology
;
surgery
;
Male
;
Middle Aged
;
Spleen
;
pathology
;
surgery
;
Splenectomy
;
Treatment Outcome
10.Radiofrequency ablation vs. hepatic resection for resectable colorectal liver metastases.
Nan HE ; Qian-Na JIN ; Di WANG ; Yi-Ming YANG ; Yu-Lin LIU ; Guo-Bin WANG ; Kai-Xiong TAO
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(4):514-518
The treatments of resectable colorectal liver metastases (CRLM) are controversial. This study aimed to evaluate the relative efficacy and safety of hepatic resection (HR) and radiofrequency ablation (RFA) for treating resectable CRLM. Between January 2004 and May 2010, the enrolled patients were given hepatic resection (HR group; n=32) or percutaneous RFA (RFA group; n=21) as a first-line treatment for CRLM. All the tumors had a maximum diameter of 3.5 cm and all patients had five or less tumors. The patient background, tumor characteristics, cumulative survival rate and recurrence-free survival rate were assessed in both groups. There were significantly more patients with comorbidities in the RFA group than those in the HR group (17 in RFA group vs. 10 in HR group; P<0.000). The mean maximum tumor diameter in the HR group and RFA group was 2.25±0.68 and 1.89±0.62 cm (P=0.054), and the mean number of tumors was 2.28±1.05 and 2.38±1.12 (P=0.744), respectively. The 1-, 3- and 5-year cumulative survival rates in the HR group were 87.5%, 53.1% and 31.3%, respectively, and those in the RFA group were 85.7%, 38.1% and 14.2%, respectively with the differences being not significant between the two groups (P=0.062). The 1-, 3- and 5-year recurrence-free survival rates in the HR group were 90.6%, 56.3% and 28.1%, respectively, and those in the RFA group were 76.1%, 23.8% and 4.8%, respectively, with the differences being significant between the two groups (P=0.036). In conclusion, as HR has greater efficacy than RFA in the treatment of resectable CRLM, we recommend it as the first option for this malignancy.
Aged
;
Catheter Ablation
;
methods
;
Colorectal Neoplasms
;
pathology
;
radiotherapy
;
surgery
;
Female
;
Hepatectomy
;
methods
;
Humans
;
Liver
;
pathology
;
surgery
;
Liver Neoplasms
;
pathology
;
radiotherapy
;
secondary
;
surgery
;
Male
;
Middle Aged
;
Neoplasm Metastasis
;
Treatment Outcome

Result Analysis
Print
Save
E-mail